市場調査レポート
商品コード
1501232
バイオ医薬品の製造能力および生産量:第21回 年次報告書と調査(2024年)2024 21st Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production |
バイオ医薬品の製造能力および生産量:第21回 年次報告書と調査(2024年) |
出版日: 2024年04月30日
発行: BioPlan Associates, Inc.
ページ情報: 英文 500 Pages; 200+ Graphs; 20+ Tables
納期: 即日から翌営業日
|
当レポートは、バイオプロセスの専門家を対象とした最も包括的・長期的な調査です。また、業界動向や考察、ビジネスチャンスにスポットを当てています。
【最新情報】今年度版では、業界の動向と今後の成長に関する分析を提供する主題専門家を追加し、各章で重要なポイントを解説しています。当レポートは505ページに及ぶデータ豊富な分析で、生産能力・生産動向・ベンチマークなどを詳細に分析し、バイオマニュファクチャリング業務における意思決定の向上に役立ちます。
The '2024 21st Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production' is the most comprehensive, longest-running study of bioprocessing professionals. We highlight industry trends, insights, and opportunities.
NEW! This year's edition provides additional Subject Matter Experts providing analysis on trends and future growth, and key takeaways in each chapter! This report's 505 pages of data-rich analysis will help improve your decision making in biomanufacturing operations, with an in-depth analysis of capacity, production trends, benchmarks, and much more.
"It is always a pleasure and honor to contribute to such an important report, capturing the state of the industry." - Stefan Schmidt, CEO, Evitria AG.
"If you really want to get under the skin of the industry, this [BioPlan report] is where you go...Everything you need to know about the biopharma industry is in the BioPlan Annual Report...is the Granddaddy of reports...many pages if you want to get under the skin of the industry, this is where you go." - Dodi Axelson, Discovery Matters Podcast, Dec 2021.
"Your report has delivered significant value to us. We use it as a fundamental part of the research for our strategic planning. This report has helped us see market shifts, such as the predicted increase in needs for biotech-focused CMOd's that we used to position our company to better serve our clients. We consider this a must-have report to keep our business focused in the right direction." - Jeff Hargroves, President, ProPharma Group.
"BioPlan Associates Annual Reports are a valuable independent resource for monitoring drug manufacturing activities, trends and future needs."- Jerold Martin, Former Pall Life Sciences.
"The BioPlan Annual Report and Survey is and has always been a must-read, as it is the most comprehensive survey and results analysis to determine trends, requirements, and new demand of the biopharmaceutical industry. The report's data and interpretation of the survey results are an invaluable tool for biomanufacturers and suppliers alike, as it thoroughly highlights the current status and future necessities. It not only is a snapshot report but a multi-year evaluation." - Maik Jornitz, President, G-Con, LLC.
"I have found each BioPlan Associates' Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production to be particularly useful in my work. As managing editor for BioProcessing Journal, I refer to my print copies of the biomanufacturing survey reports regularly when recruiting and editing manuscripts. They are valuable components of my journal production 'toolkit.'"- Marci J. Brown, Managing Editor, BioProcessing Journal.